June 30, 2020 -- Ajinomoto Bio-Pharma Services launched Ajility, a flexible drug product manufacturing platform for vaccines and therapies.
The goal of the Ajility platform is to minimize variables during technology transfer, manufacturing, and shipping processes to quickly get therapies to the clinic. Clients who use the Ajility platform will have access to Ajinomoto's process and regulatory expertise. The platform provides cost and time savings to advance drugs to market, according to the company.
The platform is designed for novel therapeutics or vaccines as well as existing drug products with new indications. The flexibility of the platform has been leveraged to streamline project configurations to be used for COVID-19 trials, U.S. Food and Drug Administration emergency use authorizations, or other desired programs.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
